News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tolero Pharmaceuticals And Eutropics Pharmaceuticals Announce Data Demonstrating Clinical Utility Of Praedicare Dx In Guiding New Drug Treatment Of CLL Patients



8/12/2014 11:02:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eutropics, Inc, (Cambridge, MA) and Tolero Pharmaceuticals, Inc, (Lehi, UT) announced today that clinical study results demonstrating a predictive biomarker for Chronic Lymphocytic Leukemia (CLL) patient response to treatment with Toleros’ experimental drug alvocidib were published in the medical journal Leukemia. The results appear in an article entitled, “Mitochondrial priming of chronic lymphocytic leukemia patients associates Bcl-xL dependence with alvocidib response.” The study, performed in collaboration with Ohio State University and Duke University Medical Centers, compared a novel algorithm readout of Eutropics’ companion diagnostic platform, Praedicare Dx, to positive patient outcome after alvocidib treatment. Importantly, a different algorithm readout of Praedicare Dx was discovered that predicts likelihood of adverse effects, providing further guidance for treatment.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES